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Does In Vitro Potency Predict Clinically 
Efficacious Concentrations?
Rasmus Jansson-Löfmark1,*, Stephan Hjorth2,3 and Johan Gabrielsson4
The in vitro affinity of a compound for its target is an important feature in drug discovery, but what remains is how 
predictive in vitro properties are of in vivo therapeutic drug exposure. We assessed the relationship between in 
vitro potency and clinically efficacious concentrations for marketed small molecule drugs (n = 164) and how they 
may differ depending on therapeutic indication, mode of action, receptor type, target localization, and function. 
Approximately 70% of compounds had a therapeutic unbound plasma exposure lower than in vitro potency; the 
median ratio of exposure in relation to in vitro potency was 0.32, and 80% had ratios within the range of 0.007 to 
8.7. We identified differences in the in vivo–to–in vitro potency ratio between indications, mode of action, target 
type, and matrix localization, and whether or not the drugs had active metabolites. The in vitro–assay variability 
contributions appeared to be the smallest; within the same drug target and mode of action the within-variability was 
slightly broader; but both were substantially less compared with the overall distribution of ratios. These data suggest 
that in vitro potency conditions, estimated in vivo potency, required level of receptor occupancy, and target turnover 
are key components for further understanding the link between clinical drug exposure and in vitro potency.
The in vitro affinity of a compound for its target is an important 
feature in drug discovery, but even more central is the question of 
how predictive in vitro properties are of in vivo therapeutic drug 
exposure. The underlying assumption is that a compound with 
high in vitro affinity and favorable in vivo pharmacokinetic prop-
erties may have a greater chance to deliver its intended clinical ac-
tion in comparison with compounds with poor pharmacokinetic 
properties and in vitro potency.1,2
It is possible to at least partly hypothesize on desired onset, 
intensity, and duration of a pharmacological response based 
on a compound’s mechanism of action. Insights into target 
occupancy relative to actual drug concentrations are also key 
parameters towards a therapeutic response.3 Thus, for receptor 
antagonists and irreversible enzyme inhibitors, it is often as-
sumed that high and/or extended target occupancy is essential, 
in contrast to agonists where these features are not necessary to 
elicit a clinical response. According to the law of mass action, 
drug concentrations ~ 3–5 times the in vitro potency (affinity 
constant Kd) would reach a target occupancy of about 80% and 
thereby possess a good chance to result in a pharmacological re-
sponse.4 Target turnover and transduction-coupling efficiency 
aspects are often neglected despite being equally important 
for in vivo ("open" system) effects. In some instances, pharma-
cokinetic–pharmacodynamic reasoning has been successful to 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 In vitro potency is commonly used alone, or in combination 
with preclinical in vivo data, to predict clinically therapeutic 
exposure levels. But there is limited knowledge regarding how 
predictive in vitro potency is in general to estimate the thera-
peutic drug exposure.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study addressed the general relationship between clini-
cal unbound therapeutic concentrations and in vitro potency, 
how they may differ depending on therapeutic indication, mode 
of action, receptor type, target localization and function, and 
potential drug discovery and development implications from 
this analysis.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 The results emphasize that generic predictions of in vivo effica-
cious concentration based on in vitro potency may be highly variable 
and may lack biological significance. The data additionally identify 
sources to variability and their relative impact upon predictions of in 
vitro–to–in vivo clinically efficacious exposure levels.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 This might provide an enlightened awareness of factors to 
consider when relating therapeutic exposure to in vitro potency. 
It also provides the scientist with a quantitative level of confi-
dence on how predictive in vitro potency alone is to estimate 
therapeutically efficacious drug exposure levels.
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remedy these shortcomings.5–11 Clearly, capricious use of mul-
tiples of efficacious in vitro concentrations in the absence of a 
clear scientific rationale may jeopardize the selection process 
as well as onwards clinical drug development. In turn, this may 
lead to underpredictions or overpredictions and ultimately er-
roneous conclusions with respect to drug efficacy as well as 
therapeutic benefit/adverse event ratio estimates. Gleeson and 
coworkers assessed the generic relationship between therapeutic 
doses, in vitro potency, and physicochemical properties.1 They 
concluded that high in vitro drug potency does not necessarily 
predict in vivo benefit, partly because of poorer pharmacokinetic 
properties.
The present study was undertaken to address, “What is the rela-
tionship between clinical unbound concentrations and in vitro po-
tency, and how can drug discovery and development benefit from 
a better understanding of this linkage?” A survey of 164 drugs was 
done to identify important points to consider when assessing new 
molecular entities. The compilation includes pharmacokinetic 
properties (clearance, bioavailability, plasma protein binding, vol-
ume of distribution, half-life, and active metabolites), clinically 
unbound concentrations (Cu,ss), intracellular or extracellular tar-
get localization, in vitro binding affinities, type of in vitro property 
parameter (target binding, function; dissociation constant (Kd), 
inhibitory constant (Ki), concentration of drug producing 50% in-
hibition of maximal inhibition (IC50), concentration of drug pro-
ducing 50% of its maximum effect (EC50)), mechanism of action, 
target type, and therapeutic area.
MATERIALS AND METHODS
Data compilation
Literature data comprising dosing regimen, pharmacokinetic properties, 
plasma protein binding, and in vitro potency were collected for a total of 164 
clinically low molecular weight (<700 g/mol) approved drugs. The infor-
mation gathered also included mechanism of action, therapeutic drug class, 
target type and location, and type of reported in vitro property (Kd, Ki, IC50, 
EC50). All data are available in the Supplement (Tables S5, S6).
In vitro potency
Drug in vitro potency parameters (Kd, Ki, IC50, and EC50) were ex-
tracted from database and literature sources (for basic definitions and 
a more in-depth description of these pivotal parameters, please see the 
International Union of Basic and Clinical Pharmacology (IUPHAR) 
update on nomenclature in receptor pharmacology by Neubig et al. 
(2003)12). The publicly accessible ChEMBL (https://www.ebi.ac.uk/
chemb l/) and IUPHAR / British Pharmacological Society (BPS) Guide 
to Pharmacology (http://www.guide topha rmaco logy.org/) databases 
were the main resources for the in vitro potency data. If they could not be 
found from these sources, literature searches via PubMed (http://www.
ncbi.nlm.nih.gov/pubme d/) were done and data extracted from original 
publications. For all compounds, we stated if the in vitro potency was 
defined as either IC50, EC50, Ki, or Kd. For the final analyses, Ki and Kd 
were converted to IC50 by a factor 2 assuming competitive inhibition 
and that substrate concentration is equivalent to its Michaelis-Menten 
constant.13 The in vitro activity for the drugs were directly related to the 
primary target indication and whenever possible, only in vitro activity 
values were used based on the human receptor. This resulted in a total of 
3963 in vitro potencies for the 164 compounds (Table S5, Supplement). 
For agents with more than one reported pharmacologically relevant in 
vitro potency target value and assay, the geometric mean value was used 
and precision was calculated.
Clinical plasma concentrations and therapeutic dose
Pharmacokinetic properties including oral bioavailability, plasma clear-
ance, volume of distribution, half-life, and plasma protein binding were 
obtained from Obach et al.14, the US Food and Drug Administration 
(www.FDA.gov), the www.drugs.com database, and from peer-reviewed 
publications. Dose and dose frequencies were mainly obtained from the 
Swedish National Medical Product Register (NMPR; https://nsl.mpa.
se/index_engli sh.htm). Dosing regimen data on drugs not available in 
the NMPR database were obtained from the drugs.com website (https://
www.drugs.com). Dose and dosing regimen were based on the partic-
ular therapeutic indication according to the Anatomical Therapeutic 
Chemical (ATC) classification system. In cases when there were different 
doses and frequencies available, the typical recommended dose was used. 
If it was stated that the dose needed to be highly individualized, the mean 
dose used or the dose level most commonly used was utilized. Details on 
each drug is available in Supplemental Table S6.
The majority of drugs (157 of 164 compounds in total) were in-
tended for oral administration and chronic/subchronic (n = 161 of 164) 
treatment.
Clinically unbound concentrations at steady state Cu,ss were derived 
using
where F corresponds to bioavailability, Dose to dose per occasion, Cl clear-
ance, and τ the dosing interval.15 The free fraction fu is the ratio of unbound 
to total plasma concentration, and is governed by density of binding sites on 
the plasma protein and drug-protein binding affinity. In the few cases where 
the drug was prescribed as a single dose administration only, we calculated the 
total area under curve (AUC), divided by 24 hours to convert this to an av-
erage drug exposure over 24 hours, to yield a clinical concentration measure. 
Peak unbound steady state plasma concentration (Cu,ss,max) at repeated dos-
ing and trough unbound steady state concentration (Cu,ss,min) prior to next 
dose were also evaluated and are described in the Supplement. The ratio of 
unbound plasma concentrations to in vitro potency was calculated as Cu,ss/in 
vitro potency, and is denoted Ratio. Subset analyses were also performed 
based on different potency values (see Supplement).
Additional drug descriptors
To provide further insight into the relationship between clinical un-
bound plasma concentration and in vitro potency, information was also 
gathered about
• Ligand target class—i.e., G protein-coupled receptor (GPCR), 
enzyme, ion channel, transporter/reuptake protein, or nuclear 
receptor
• Ligand property/mechanism of action—i.e., agonist, antago-
nist, inhibitor, or modulator
• Presence of pharmacologically active metabolites—i.e., (i) no active 
metabolites known to contribute to the pharmacological effect, (ii) 
known active metabolites, or (iii) active metabolites present, but un-
clear how they contribute to the pharmacological effect
• If the drug is given as a racemate or as the pure isomer
• Extracellular or intracellular localization of the drug target
• Drug therapeutic indication area according to the ATC classifi-
cation system
• Type of reported in vitro potency measure—i.e., Kd, Ki, EC50, 
or IC50
The collated data set included a broad range of chemical and phar-
macological classes with varying pharmacokinetic properties, modes 
(1)Cu,ss=
F ⋅Dose ⋅ fu
Cl ⋅휏
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of action, ligand target type, and therapeutic indication (Table S6, 
Supplement).
Exploratory and statistical analyses
Data of this analysis were presented graphically as histograms, cumu-
lative frequency plots, and scatter plots. Comparisons between groups 
were done based on means of log-transformed data, and corresponding 
85% confidence intervals of the mean value (i.e., precision). The 85% 
confidence intervals, rather than 90% confidence intervals, were used 
to assess differences between groups at the ~ 5% level with the assump-
tion that Standard Errors between groups were approximately equal.16 
Additionally, the nonparametric Kolmogorov-Smirnov test (K-S test) 
was used to assess whether the different groups differed between each 
other based on their cumulative Ratio distribution profiles.17
Range and variability data were also analyzed. To this end, we assessed 
within-drug in vitro potency variability for each drug with three or more 
reported in vitro potency values. After establishing median values, we ar-
ithmetically generated corresponding variability distribution curves ex-
pressed as percentiles with the median set as the 50th percentile. Assuming 
that the drug data used in this exercise are indeed representative of the class 
in question, the derived percentile curves of in vitro potency provide an 
estimate of the typical distribution of within-drug class variability around 
the 50th percentile.
To evaluate variability within each drug target and mode of action, 
the ratios and the percentiles were normalized to the 50th percentile, and 
thereafter median percentiles were generated across the different classes 
of drugs.
To assess potential influences of covariates on the relationship between 
Cu,ss and in vitro potency, a nonlinear mixed effects modeling approach was 
used. This was done according to the equation
where the parameters slope, covariate, and intercept were fitted to the 
data. Covariateindividual value is the individual value for each drug and the 
Covariatemedian value is the median covariate value for the data set. An 
exponential (exp) error model was used (Observation = Prediction × ex-
p(Residual Error)). The inclusion of covariates was assessed by using the log 
likelihood ratio, in which the difference in the objective function value 
between the full and reduced models was asymptotically χ2 distributed. 
A decrease in the objective function value of 3.84 between two nested 
models (1 degree of freedom) was considered to indicate a statistically 
improved model (P  <  0.05). Additionally, the 90% confidence inter-
val of the covariate parameter was also assessed, if different from zero. 
Data were modeled using Phoenix WinNonlin 8.1 (Pharsight Certara, 
Princeton, NJ), using the naive-pooled method. The following covari-
ates were evaluated: drug lipophilicity (logP), molecular weight, clear-
ance, bioavailability, half-life, volume of distribution, unbound fraction 
in plasma, dosing frequency, and daily dose (Supplement, Table S4). 
Graphical generations, statistical analyses, and covariate analyses were 
either done using Microsoft Excel for Office 365 (Microsoft, Redmond, 
WA) or Phoenix WinNonlin 8.1 (Pharsight Certara, Princeton, NJ).
RESULTS
Overall relationship of Ratios
The primary results in terms of unbound clinical concentrations–
to–in vitro potencies, denoted Ratio(s), are shown in Figure  1, 
where log Ratios are plotted against frequency and cumulative fre-
quency. Notably, ~ 70% of all Ratios are less than unity; the me-
dian ratio was 0.32, and fewer than 10% of compounds displayed 
Ratios exceeding 10.
Ratios by therapeutic indication: ATC categories and overall 
comparison of drug target variabilities
Drugs categorized as antiinfectives (ATC code J) and antipar-
asitic/insecticides/repellents (ATC code P), represent a distinct 
group. These agents are enzymatic inhibitors with Ratios generally 
higher as compared with drugs for all other therapeutic indications 
(Figure 2 and Table S2). As the drugs in this group act on non-
human cell targets, they were excluded from subsequent analyses.
(2)Cu,ss = slope× In vitro potency+Covariate
×
(
Covariateindividual value−Covariatemedian value
)
+ intercept
Figure 1 Distribution of the unbound plasma concentrations–
to–in vitro potency ratio of 164 compounds. Left axis, divided 
into logarithmically increasing bins. Bins are divided into threefold 
categories. Right axis, cumulative frequency vs. the ratio. [Colour 
figure can be viewed at wileyonlinelibrary.com]
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Figure 2 Cumulative frequency vs. Ratio divided according to the 
Anatomical Therapeutic Chemical (ATC) Classification System. The 
pale wide blue line is for all compounds. A, alimentary tract and 
metabolism; C, cardiovascular system; G, genito-urinary system 
and sex hormones; H, systemic hormones excluding sex hormones, 
insulins; J, antiinfectives for systemic use; L, antineoplastic and 
immunomodulating agents; M, musculo-skeletal system; N, nervous 
system; P, antiparasitic products, insecticides and repellents; R, 
respiratory system; S, sensory organs; V, antidotes. *J, P group (red 
line) deviated significantly (P < 0.05) from the remaining data set 
based on the nonparametric Kolmogorov-Smirnov test. [Colour figure 
can be viewed at wileyonlinelibrary.com]
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A relatively low Ratio variability was observed within some 
therapeutic classes e.g., genito-urinary system and sex hormones 
(ATC code G) and musculoskeletal system (ATC code M). When 
divided into second-level therapeutic subgroups (Figure S4) and 
removing drugs with potentially confounding contributions of re-
ported active metabolites, 7 of 15 ATC groups had a prediction 
coefficient (R2) of 0.63–0.92, when using a linear regression of the 
log-transformed data. The remaining nine groups showed an R2 
value of 0.41 or less. Notably, agents acting on the renin–angio-
tensin system (ATC code C09) displayed a very poor correlation 
(R2 = 0.03, n = 7).
The overall in vitro assay variability derived from within-drug 
medians and 10th and 90th percentiles (centered around the corre-
sponding 50th percentile) was 0.32 and 3.0, respectively, thus rep-
resenting a 10-fold range (Figure 4). Ten targets in our database 
had four or more drugs per target and the same mode of action (a 
total of 55 compounds, e.g., 5-hydroxytryptamine (HT) reuptake 
inhibitors, 5-HT1D receptor agonists, etc.). In this target excerpt 
the absolute median 10th and 90th percentile (centered around the 
corresponding 50th percentile) potency Ratio varied between 0.25 
and 13, respectively, among the groups (Supplement, Figure S7), 
thus representing an ~ 50-fold range.
For comparison, the global Cu,ss/in vitro potency Ratio vari-
ability across all classes of drugs (10th and 90th percentile centered 
around the corresponding 50th percentile) amounted to a 1,275-
fold range (Figure 4).
Ratios by mechanism of action or receptor type
Among the different modalities and mechanisms (excluding an-
timicrobial & insecticide agents, see above) the highest Ratios 
across all classes were found for reuptake/transporter inhibitors 
(Figure  3). Compounds in this class were primarily serotonin 
(5-HT) or mixed noradrenaline/5-HT transporter inhibitors. 
However, there was an overlap in the 85% confidence interval 
of Ratios compared with other classes (Supplement, Table S1), 
and hence, no statistically significant differences. The lowest and 
highest Ratio variability among analyzed classes was seen with 
GPCR antagonists and enzyme inhibitors, respectively.
Ratios by localization of target, the presence of active 
metabolites, and covariate analysis
Drugs aimed at intracellular targets tended to have lower Ratios 
compared with extracellular targets (Figure  5, left). However, 
80% of agents for intracellular targets were enzyme inhibitors, 
and the mode of action therefore substantially different compared 
with the other groups of ligands.
Compounds with pharmacologically active metabolites had in 
general a lower Ratio compared with those with no reported active 
metabolites (Figure 5, right). No major differences were seen for 
pure isomer drugs vs. drugs given as racemic mixtures.
A number of covariates appeared to be influencing the ratios. 
The covariates’ bioavailability and unbound fraction in plasma cor-
related positively, whereas logP and molecular weight correlated 
negatively to the Ratios. However, the residual error was only mar-
ginally improved irrespective of covariate examined (Supplement, 
Table S4).
The Ratios were also explored according to type of reported of 
in vitro potency (EC50, IC50, or Ki, Kd; see Supplement Figure 
S6). Based on the 10th to 90th percentile, in vitro IC50 or Ki values 
displayed numerically less variability as compared with EC50 or Kd. 
When conducting this assessment for matched compounds, for in 
vitro IC50 vs.  Ki (available for 90 compounds) and based on the 
10th and 90th percentiles, in vitro IC50 had a threefold lower range 
compared with Ki. For in vitro EC50 vs. Ki values (19 compounds) 
we observed a similar variability. For in vitro IC50 vs. in vitro EC50 
(24 compounds) we observed an approximately twofold lower 
range for in vitro EC50 vs. in vitro IC50. All data are available in the 
Supplement (Table S6).
DISCUSSION
Overall assessment of Ratios
We sought to provide a more detailed insight into how drug in 
vitro target potency relates to clinically effective concentrations. 
Data on 164 registered drugs were collated and reviewed with re-
spect to their clinically effective unbound plasma exposures to in 
vitro potency relationship Ratio. The Ratios were also assessed vs. 
therapeutic indication area, mode of action, receptor type, race-
mate or isomer, pharmacologically active metabolites, and intra-
cellular or extracellular target location.
The relationship was stronger between in vitro potency and 
therapeutic unbound plasma exposure compared with daily dose 
(Supplement Figure S2), which is consistent with the generally 
accepted notion that the unbound plasma concentrations "drive" 
the pharmacological effect of small molecule drugs.1,9,18
A high variability was seen in the Ratios independently of drug 
classification. The accumulated observations demonstrate that 
Figure 3 Cumulative frequency of Ratios for compounds classified 
by mechanism of action and target type. The pale wide blue line 
is for all compounds. Antiinfectives for systemic use (ATC code J); 
antiparasitic products, insecticides, and repellents (ATC code P) were 
excluded. GPCR, G protein-coupled receptor. [Colour figure can be 
viewed at wileyonlinelibrary.com]
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prediction of therapeutic exposure based on multiples of in vitro 
potency should be treated with caution since this metric is highly 
multifactorial. However, the findings may be used for statistical as-
sessment to interpret drug exposure levels in in vivo pharmacolog-
ical studies. Additionally, this probability assessment can further 
be divided into therapeutic indications, receptor type, and target 
localization.
Therapeutic indication areas (ATC) and overall comparison 
of drug target variabilities
Antimicrobials (antiinfectives for systemic use, antiparasitic prod-
ucts, and insecticides and repellents; ATC classes J & P) showed 
a higher Ratio in contrast to ligands for human cell targets. 
Presumably this relates to the need to ensure adequate penetration 
of drug to the target site and to provide efficient eradication of the 
infectious (or parasitic) matter, thereby optimizing recovery.19,20 It 
is worth recalling in this context, also, that agents like these treat the 
cause of disease rather than symptoms thereof. In turn, to achieve 
the desired therapeutic action, a saturation or supersaturation of 
the culprit microbial/parasitic target—accompanied by high Cu,ss 
exposure—is therefore more probable by compounds in this class.
In certain classes of biological pathways and within certain indi-
cations, the in vitro potency can be fairly predictive of therapeutic 
exposure. Thus, dividing compounds into subgroups based on the 
therapeutic classification system ATC revealed several classes of 
drugs (e.g., drugs for acid-related disorders, cardiac arrhythmia, hy-
pertension, beta-adrenoceptor blocking agents, analgesics, psycho-
leptics, and for obstructive airway diseases) with a high correlation 
between Cu,ss and in vitro potency, although it should be noted 
that most of these correlations are based on a limited number of 
agents (Supplement Figure S5, Table S2).
Generally, the data suggest that the principal source of variabil-
ity is between targets rather than within in vitro assays or within 
same drug target and mode of action. Thus, the median variability 
observed that could be attributed to in vitro assay contributions 
was only 10-fold, whereas the global variability range was 1,275-
fold (Figure 4). Potential reasons for this difference are discussed 
further below.
Reasons for variations in the ratio
The median Ratio across all drugs was below 1.0 but highly vari-
able and independent of mechanism of action. Potential reasons 
include promiscuous drug action, suboptimal in vitro assay con-
ditions (temperature, target expression, or in vitro test compound 
exposure), interference from pharmacologically active metabo-
lites, and target turnover differences.
It is unlikely that the main reason for the variability is drug pro-
miscuity. Although drug candidates can be promiscuous, the level 
seems to vary according to the data set used.21–23 Our work did not 
address pharmacological effects per se, but rather clinically effective 
plasma concentrations and their relative value to in vitro potency 
of the claimed primary target. Many of the drugs examined are also 
considered selective for their primary target, particularly taking 
the unbound exposures into consideration. To minimize the risk 
of confounding promiscuity we assessed potency for the primary 
target indication only and strove to select the pharmacologically 
most relevant in vitro measures. Given this, we judge nonselectiv-
ity in drug target action to be a but minor confounder within this 
work, although we cannot entirely exclude that a smaller subset of 
drugs bind to other than the primary receptors and may add to the 
variability observed.
Only a small portion of the spread in the observed Ratios within 
this work may be accounted for by in vitro variability. For several 
drugs in this work there were multiple reported in vitro potency 
values for one and the same target, and indeed the potency for 128 
of 164 compounds was based on three or more data sources. For 
these compounds the median coefficient of variation of the geo-
metric mean value was 185%, and the majority of the in vitro po-
tency values had variabilities within a factor of ten. As mentioned 
elsewhere within this manuscript, sources of in vitro variability 
were likely multifactorial. Within this work we did not assess the 
influence of irreversible/covalent target in vitro binding;24 neither 
did we mechanistically corroborate potential nonspecific binding 
in the in vitro system.
Pharmacokinetic and target matrix considerations
Compounds with reported pharmacologically active metabolites 
displayed an approximately threefold leftward shift in the Ratios 
compared with compounds without (Figure  5, right graph). 
This emphasizes the need to account for the contribution of ac-
tive metabolites for Ratio assessments and clinically effective 
concentrations.25
Our data suggest that intracellular vs. extracellular distribution 
may also be a factor relevant to consider in the drug discovery phase. 
Indeed, there was a trend towards smaller Ratios for intracellular 
Figure 4 Cumulative percentile distribution when centered around 
their 50th percentiles. Blue line is the percentile distribution for all 
compounds (n = 164) of the Ratio when centered around the 50th 
percentile (n = 164). Green line is the reported in vitro potency 
for the same drug centered around their 50th percentile for all 
compounds (128 compounds which had 3 or more reported in vitro 
potencies corresponding to a total of 3963 in vitro potencies) and 
the median distribution is depicted. [Colour figure can be viewed at 
wileyonlinelibrary.com]
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compared with extracellular targets. This said, in our database all 
drugs with intracellular targets were either enzyme- or nuclear re-
ceptor-acting agents, whereas agents for extracellular targets were 
either GPCR (58%), ion channel (23%), transporter/reuptake 
(12%), or enzyme-acting (8%) ligands, thus limiting interpreta-
tions on the impact of target localization as such. For comparison, 
a high Ratio has also been described to be required for an inhibitor 
of an extracellular (membrane-bound) enzyme to elicit a clinically 
pharmacological effect.26 There have been efforts to improve the 
understanding of intracellular drug exposure and methods to assess 
this for preclinical drug candidates.27–29 A deeper understanding 
of the relationship between free drug concentrations and distribu-
tion in plasma and within tissues is clearly needed.30
The steady-state unbound exposures (Cu,ss) were used for the 
Ratio calculations. Exploration of Cu,ss,max and Cu,ss,min vs. in vitro 
potency showed a larger variation when Cu,ss,min instead of Cu,ss,max 
or Cu,ss was used (Figure S3). This is in line with the requirement 
for a high and sustained drug occupancy for therapeutic responses 
via many of the targets included in this study (e.g., enzymes and 
reuptake transporters; see, ref.3, but otherwise this analysis did not 
cast any further light on the general Ratio assessment.
Covariate analyses
In the analysis of the impact of covariates upon the Ratios, drug 
bioavailability and unbound fraction in plasma were positively 
correlated, while logP and molecular weight were negatively cor-
related to Ratios (Supplement, Table S4). These changes were, 
however, mostly minor, and any interpretations of these analyses 
require caution. In general, evaluation of covariate influences 
would require further investigations and also be separately eval-
uated with a training and a test set to draw any conclusions with 
regard to their possible importance.
In vivo potency vs. target turnover
It is evident that several factors contribute to the in vivo potency 
readout, not only linked to drug-related features. Indeed, an 
extended expression of in vivo potency EC50 was recently derived, 
which incorporates both binding affinity (Kd =  koff/kon,  where 
kon and koff  denote the second-order on and first order rate of li-
gand-receptor binding), ligand-target binding rates, and target 
turnover properties.31 The in vitro drug potency measure primar-
ily assesses binding affinities (e.g., the Kd parameter) but typi-
cally neglects ligand-target kinetics and target turnover. Highly 
variable Ratios across compounds and targets are therefore not 
surprising.31,32 A clear in vitro–to–in vivo correlation is not to be 
expected unless target-to-complex kinetics are constant or close to 
unity, and ligand-target removal is relatively slow (ligand-target 
complex elimination rate << ligand-target off-rate).31,32 Failure to 
take target turnover and target-ligand complex characteristics into 
account is therefore likely to result in less predictable in vivo prop-
erties from in vitro potency readouts.
Based on the aforementioned, we surmise that the biological 
variation between therapeutic unbound exposure levels relative to 
in vitro potency predominantly originates from:
1. Substantial variability in the observed in vivo potency vs. in 
vitro drug affinity owing to the impact of in vivo target kinet-
ics. For example, recent work by Gabrielsson et al.31 quotes 
data excerpted from six literature studies. Recalculating in vivo 
EC50–to–in vitro Kd (koff/kon) Ratios from these studies results 
in ranges from 0.22 to 66, thus a factor of 300-fold difference 
in turnover rates among the targets in question. While these 
examples were large molecule (antibody) targets, similar find-
ings have been reported also for small molecules. In particular, 
agents with targets in the circulation compartment and/or that 
have slow target dissociation rates koff are expected to show 
in vivo potencies highly dependent upon the corresponding 
target turnover rate (kdeg/kon, where kdeg is target degradation 
rate, see Gabrielsson et al.31
2. Differences in the level of in vivo target occupancy required for 
clinical efficacy across targets, dependent both upon the level of 
endogenous tone at the target, drug mechanism of action (e.g., 
GPCR agonist vs. antagonist), and target amplification properties 
(receptor reserve; see further studies, e.g., Grimwood & Hartig, 
20093). For example, a high efficacy agonist drug at the dopa-
mine D2 receptor may elicit a near-maximal receptor response 
already at receptor occupancies <10–20%, whereas 70–80% re-
ceptor occupancy by antagonists at the same target is typically 
required for therapeutic efficacy in schizophrenia. It follows that 
marked differences in plasma concentrations are to be expected, 
depending on what level of receptor occupancy may be required 
for beneficial effects in vivo, even for the very same target site. 
The difference between 20 to 80% receptor occupancy usually 
corresponds to at least a 10-fold difference in drug exposure. A 
possible corollary is that the curve for GPCR agonists would be 
shifted ~ threefold to the right had in vitro EC10 or EC20 rather 
than EC50 been used for Cu,ss / in vitro potency calculations in 
this class. Conversely, the curve for GPCR antagonist agents 
would be shifted ~ threefold leftward had the in vitro EC70 or 
EC80 rather than EC50 been used in the same manner.
3. Factors related to the experimental model used to determine 
in vitro potency (e.g., assay conditions, target binding, or 
Figure 5 Cumulative frequency vs. Ratio. Left, graph marked 
according to target location (intracellular, extracellular). Four 
compounds of unclear or mixed designation regarding extracellular 
vs. intracellular target localization were excluded. Right, graph 
marked according to known contribution of active metabolites or not. 
Five compounds were excluded that had reported metabolites, but it 
was unclear whether or not these contributed to the pharmacological 
effect. Antiinfectives for systemic use (ATC code J); antiparasitic 
products, insecticides, and repellents (ATC code P) were excluded. 
[Colour figure can be viewed at wileyonlinelibrary.com]
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functional type of assay). For example, the 10th and 90th per-
centile factors were 0.31 and 3.3 of the geometric mean value 
when there were multiple in vitro potency values available for 
the same drug in our database; that is, roughly a 10-fold range.
These three reasons are the likely main sources of variability 
between in vitro potency and in vivo clinical therapeutic expo-
sure relationships, and illustrate that a large variability between 
them is to be expected. Indeed, combining items 1–3 (i.e., 300-
fold, 10-fold, and 10-fold range) would result in an even wider 
theoretical spread compared with the ~ 1300-fold range (10th 
to 90th percentile) of Ratios observed within the present work. 
As described above, in terms of the main sources of variability, 
we found that within–in vitro assay conditions vary the least (~ 
10-fold), within-target varies moderately (~ 50-fold) and could 
vary less if having identical in vitro assay conditions, whereas 
cross targets vary the most (~ 1300-fold). Cross-target ratios are 
a conglomerate of variability in in vitro assays, desired level of oc-
cupancy, and target turnover, whereas within the same target and 
mode of action variability may be less dependent on differences 
in occupancy level.
The high variability in Ratios across compounds should also be 
considered in the context of safety assessments of drug candidates. 
Essentially, this analysis proposes that quantitatively predicting in 
vivo drug exposure in relation to any in vitro potency safety assess-
ment should be carried out with great caution, and emphasizes the 
need to assess safety in the in vivo setting. This is in alignment with 
the success of early implementation of safety studies in vivo for pre-
clinical drug candidates.33
Overall conclusions
The aim of this work was to assess what factors may influence the 
precision of predictions from (low-molecular) drug in vitro po-
tency to clinically efficacious (steady-state) unbound concentra-
tions. Our analysis has
1. Described the overall distribution of in vivo–to–in vitro Ratios 
for a broad set of clinically launched drugs (n = 164) and their 
corresponding targets; 70% of these Ratios were found to be at 
or below unity
2. Indicated a modest trend to higher Ratios for drugs inhibiting 
transporter/reuptake sites, and to lower Ratios for drugs with 
known active metabolites or those acting at intracellular vs. ex-
tracellular targets; except for these trends, no major differences 
were distinguished among drug Ratios based on either substrat-
ification by means of the ATC classification scheme, type of 
target (enzyme, GPCR, ion channel, etc.), mechanism of action 
(agonist, antagonist, inhibitor, or modulator), or type of assay 
and measure used in the in vitro drug characterization (EC50, 
IC50, Kd, or Ki)
3. Identified some key factors that contribute to the global, nearly 
1,300-fold, range of Ratios across all drugs examined; based on 
closer scrutiny of the components involved, the largest variabil-
ity source appears to be in vivo biology related (e.g., wide range 
of target kinetics), whereas the in vitro assay variability appears 
to contribute the least, with drug-target occupancy-response 
variability adding to the total Ratios observed
These results underscore that predictions of in vivo efficacious 
concentration based on generic in vivo–to–in-vitro Ratios may 
be highly variable, and may even lack biological significance. To 
advance compound selection during drug discovery, we would 
like to stress the need to further develop more in vivo–like in 
vitro systems and setups, such as sophisticated cell/organ ar-
rangements, microphysiological systems, and as well the usage of 
mechanistic-based pharmacokinetic–pharmacodynamic model-
ing.34–39 The current analysis also strongly supports further in 
vivo pharmacological evaluation of test compounds, even if they 
display a low Ratio. Our data suggest that in vitro potency assay 
conditions, in vivo potency estimations from pivotal disease 
models, defining the required level of receptor occupancy, and 
probing in vivo target turnover properties are key components 
to the understanding of the links between clinical drug exposure 
and in vitro binding affinity.
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